Quincey James, Chairman and CEO, has demonstrated a clear selling bias in recent insider transactions across two companies: Pfizer (PFE) and Coca-Cola (KO). Over 25 reported trades, James has sold $102.9 million worth of shares compared to $14.2 million in purchases, with all five most recent transactions being sales. The activity in Coca-Cola shares has been particularly significant, including a $19.8 million sale on March 3, 2026, following a $26 million disposal on February 3, 2026, and earlier multi-million dollar sales in 2025 and 2024. By contrast, Pfizer transactions have been smaller and more routine, consisting entirely of acquisitions under $38,750 each, with the last recorded purchase occurring on December 31, 2025.
James’s trading pattern shows consistent divestment in Coca-Cola, with no buys in KO shares since at least 2023, while maintaining a steady but modest accumulation of Pfizer stock through automatic periodic purchases. The sales in KO have been executed through multiple transaction types, including open-market sales (code S) and gifts or other transfers (code F), with the largest disposals clustered in early 2026. The absence of recent buying activity in either company—combined with the substantial sell-side volume in Coca-Cola—suggests a deliberate reduction in exposure to KO, while the PFE holdings appear to be part of a long-term, automated accumulation strategy given their fixed dollar amounts and quarterly frequency.
AI-assisted summary